Cereno Scientific Reports Favorable Safety and Tolerability After 12 Months of CS1 Treatment in PAH From the Expanded Access Program

Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program

/PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare...

Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program - PressReach

Open the article to view the coverage from pressreach.com

Cereno reports positive data from CS1 treatment in PAH - BioTuesdays

Cereno Scientific (NASDAQ First North: CRNO B) has announced initial learnings from its 12-month expanded access program with lead candidate, oral, once-daily CS1, in pulmonary arterial hypertension (PAH), confirming favorable safety and tolerability over long-term treatment. According to Cereno, the data is consistent with previous Phase 2a results. In a statement, Rahul Agrawal, CMO and head of R&D at Cereno, commented, “These results provide …